Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|October 4, 2005
B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancerArturo SalaThe Journal of Pathology|May 18, 2016
Cutaneous cylindroma: it's all about MYBGabriele Corda, Arturo SalaOncogenesis|February 27, 2021
MYB oncoproteins: emerging players and potential therapeutic targets in human cancerYlenia Cicirò, Arturo SalaNeuroscience Letters|December 31, 2002
DNA damage or growth factor withdrawal does not evoke activation of MYB transcription factors in neuronal cancer cell linesGabriella Pagnan, Arturo SalaScientific Reports|February 23, 2024
Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapiesYlenia Cicirò, Denise Ragusa, Arturo SalaThe Journal of Biological Chemistry|July 29, 2003
Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activityGiorgia Santilli, Bruce J Aronow, Arturo SalaThe Biochemical Journal|November 14, 2003
B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblastsLucia Cicchillitti, Sergio A Jimenez, Arturo Sala, et al.Oncoimmunology|July 30, 2013
Catechins and antitumor immunity: Not MDSC's cup of teaGiorgia Santilli, John Anderson, Adrian J Thrasher, et al.Blood Cells, Molecules & Diseases|June 26, 2007
B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survivalRebekka Schwab, Alessandro Caccamo, Saverio Bettuzzi, et al.Oncotarget|May 24, 2012
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastomaFrancesco Sottile, Ilaria Gnemmi, Sandra Cantilena, et al.Pageof 4